SCHEMBL4891700

SCHEMBL4891700

Cc1ccccc1-c1ccc2ncnc(Nc3ccc(N4CCOCC4)cc3)c2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 13/20 0.67
MAPK1 P28482 10/20 0.67
TSHR P16473 10/20 0.67
ALDH1A1 P00352 10/20 0.67
CYP2C19 P33261 10/20 0.67
HIF1A Q16665 3/20 0.67
MAPT P10636 5/20 0.66
HTT P42858 2/20 0.66
AHR P35869 1/20 0.66
CYP1A2 P05177 12/20 0.65
CYP3A4 P08684 12/20 0.65
CYP2D6 P10635 9/20 0.65
USP2 O75604 7/20 0.65
HSD17B10 Q99714 2/20 0.65
PI4KB Q9UBF8 1/20 0.62
LMNA P02545 6/20 0.55
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
CYP2C9 P11712 2/20 0.52
NPSR1 Q6W5P4 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4008515 0.87 MAPT (0.80) CLK4MAPK1TSHRALDH1A1CYP2C19
SCHEMBL14026142 0.86 MAPK1 (0.72) CLK4MAPK1TSHRALDH1A1CYP2C19
SCHEMBL15639369 0.83 MAPT (0.55) CLK4MAPK1TSHRALDH1A1CYP2C19
SCHEMBL4891690 0.83 MAPK1 (0.59) CLK4MAPK1TSHRALDH1A1CYP2C19
SCHEMBL14026144 0.83 MAPT (0.77) MAPK1ALDH1A1MAPTHTTAHR
SCHEMBL4007152 0.82 MAPK1 (0.72) CLK4MAPK1TSHRALDH1A1CYP2C19
SCHEMBL4013688 0.81 MAPK1 (0.67) CLK4MAPK1TSHRALDH1A1CYP2C19
SCHEMBL4890693 0.81 PI4KB (0.68) CLK4MAPK1TSHRALDH1A1CYP2C19
SCHEMBL17075814 0.81 MAPK1 (0.63) CLK4MAPK1TSHRALDH1A1CYP2C19
SCHEMBL4895102 0.80 MAPT (0.63) MAPK1ALDH1A1MAPTHTTAHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents ARROW THERAPEUTICS LIMITED (GB) 2008-12-18 US disclosed
EP-1748991-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS Arrow Therapeutics Limited (GB) 2007-02-07 EP disclosed
WO-2005105761-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS ARROW THERAPEUTICS LIMITED (GB) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents EIF2AK2, MAVS, IRF3 CLK4 2882/4885MAPK1 1945/4885TSHR 3306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.